This might, therefore, partially restore PD‐L1/PD‐1 function by providing more PD‐L1 binding sites to impair the neutralization efficiency of the antibodies.[9] However, the mechanism by which PD‐L1 is dysregulated in tumor cells to evade immune surveillance, especially with regard to its intracellular trafficking, remains elusive. The gene discussed is PDCD1; the disease is neoplasm.